Cargando…
Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer
BACKGROUND: Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of patients will be considered for palliative treatment at some point in their disease. Despite recent advances, the prognosis remains poor, with a median overall survival of 12–18 months. Liquid biopsy...
Autores principales: | Kapeleris, Joanna, Müller Bark, Juliana, Ranjit, Shanon, Irwin, Darryl, Hartel, Gunter, Warkiani, Majid Ebrahimi, Leo, Paul, O'Leary, Connor, Ladwa, Rahul, O'Byrne, Kenneth, Hughes, Brett G.M., Punyadeera, Chamindie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305346/ https://www.ncbi.nlm.nih.gov/pubmed/35874074 http://dx.doi.org/10.1016/j.heliyon.2022.e09971 |
Ejemplares similares
-
Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
por: Kapeleris, Joanna, et al.
Publicado: (2022) -
Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition
por: Kapeleris, Joanna, et al.
Publicado: (2022) -
Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer
por: Kapeleris, Joanna, et al.
Publicado: (2020) -
Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets
por: Kulasinghe, Arutha, et al.
Publicado: (2019) -
The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells
por: Kulasinghe, Arutha, et al.
Publicado: (2020)